Chongqing McForrest New Pharmaceutical

McForrest is a clinical-stage biopharmaceutical company based in Chongqing, China, specializing in the discovery and development of innovative small molecule therapeutics. The company focuses primarily on metabolic and endocrine disorders, with a robust pipeline targeting Type 2 diabetes, chronic kidney disease, and hyperuricemia. Their lead programs include advanced SGLT2 inhibitors and DPP-4 inhibitors designed to provide improved efficacy and safety profiles for patients with metabolic syndrome. McForrest integrates internal R&D with strategic manufacturing capabilities to advance its candidates from early discovery through late-stage clinical trials.